TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7969965

Group type: COMPARATOR
Intervention: Selegiline 40 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Selegiline
Number of subjects: 17
Study: 3583073

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine at 1800 h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine at 2200 h
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo at 1800 h and 2200 h
Number of subjects: 12
Study: 31535360

Group type: EXPERIMENTAL
Intervention: Overnight surgery (Group 1)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Routine discharge after three days (Group 2)
Number of subjects: 200
Study: 29212839

Group type: EXPERIMENTAL
Intervention: Standardized predialysis systolic BP of 110‐140 mmHg (intensive arm)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standardized predialysis systolic BP of 155‐165 mmHg (standard arm)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Intensive arm
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard arm
Number of subjects: 126
Study: 27902836

Group type: EXPERIMENTAL
Intervention: Internet CBT-I (Sleep Healthy Using the Internet [SHUTi]), a 6-week fully automated, interactive, and tailored web-based program.
Number of subjects: 303

Group type: COMPARATOR
Intervention: Internet patient education program (control group), providing nontailored and fixed online information about insomnia.
Number of subjects: 303
Study: 25948863

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/emtricitabine plus atazanavir/ritonavir (ATV/r)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/emtricitabine plus darunavir/ritonavir (DRV/r)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate/emtricitabine plus raltegravir (RAL)
Number of subjects: 328
Study: 24245491

Group type: EXPERIMENTAL
Intervention: Integrated intervention (cognitive behavioral therapy) for alcohol, anxiety, and/or depression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual counseling care for alcohol problems
Number of subjects: 0
Study: 21961780

Group type: EXPERIMENTAL
Intervention: STAR intervention
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control group (brief educational program)
Number of subjects: 185
Study: 18953056

Group type: EXPERIMENTAL
Intervention: Immunization against Abeta42
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unimmunized controls
Number of subjects: 20
Study: 16611342

Group type: EXPERIMENTAL
Intervention: Early CsA‐ME (8 mg/kg/day starting on day 0)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Delayed CsA‐ME (8 mg/kg/day starting on day 6)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Early CsA‐ME
Number of subjects: 197

Group type: COMPARATOR
Intervention: Delayed CsA‐ME
Number of subjects: 197
Study: 12659616

Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 10755246

Group type: EXPERIMENTAL
Intervention: Ofloxacin (300 mg bd for 7 days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Trimethoprim‐sulphamethoxazole (TMPSMX; 160‐800 mg bd) or alternative therapy
Number of subjects: 42
Study: 8610430

Group type: EXPERIMENTAL
Intervention: High-dose fluconazole (400 mg/day)
Number of subjects: 21
Study: 1360426

Group type: EXPERIMENTAL
Intervention: Informed consent forms used in contraceptive clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Readability assessment using SMOG formula
Number of subjects: 0
Study: 6721969

Group type: EXPERIMENTAL
Intervention: Subarachnoid blockade
Number of subjects: 148

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 148
Study: 30726985

Group type: EXPERIMENTAL
Intervention: mCare app
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard-of-care telephone
Number of subjects: 50
Study: 29105987

Group type: EXPERIMENTAL
Intervention: Ketone Ester (KE)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Isocaloric Dextrose (DEXT)
Number of subjects: 15
Study: 25896985

Group type: EXPERIMENTAL
Intervention: Internet group (n=16)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Face-to-face group (n=14)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (n=16)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 55
Study: 25118263

Group type: EXPERIMENTAL
Intervention: Pinhole glasses
Number of subjects: 48
Study: 22776066

Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention (3 months intervention from an occupational therapist)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 900
Study: 20517149

Group type: EXPERIMENTAL
Intervention: Phototherapeutic keratectomy (PTK)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Amniotic membrane transplantation (AMT)
Number of subjects: 25
Study: 17845111

Group type: EXPERIMENTAL
Intervention: Placebo-tailored intervention/no priming
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Placebo-tailored intervention/priming
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standard intervention/no priming
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standard intervention/priming
Number of subjects: 210
Study: 15670980

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus high dose multiple antioxidants (ascorbic acid 6100 mg/day, dl-alpha-tocopherol 1050 mg/day, beta-carotene 60 mg/day)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Chemotherapy alone (paclitaxel and carboplatin)
Number of subjects: 136
Study: 12135220

Group type: EXPERIMENTAL
Intervention: Urethral angle measurement
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Urethrovesical mobility measurement
Number of subjects: 73

Group type: COMPARATOR
Intervention: Ultrasound variables comparison
Number of subjects: 73
Study: 11763255

Group type: EXPERIMENTAL
Intervention: Monocular viewing condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternate fixation with no binocular time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternate fixation with binocular time
Number of subjects: 0
Study: 9250553

Group type: EXPERIMENTAL
Intervention: Patients with AFF
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 8341893

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 11
Study: 3767432

Group type: EXPERIMENTAL
Intervention: 2 ppm formaldehyde exposure
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 2 ppm formaldehyde exposure with moderate exercise
Number of subjects: 15
Study: 30319663

Group type: EXPERIMENTAL
Intervention: Sinomenine (SIN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 0
Study: 27716152

Group type: EXPERIMENTAL
Intervention: Low-dose carvedilol (maximum dose: 12.5 mg/day)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Low-dose carvedilol
Number of subjects: 250
Study: 26985269

Group type: EXPERIMENTAL
Intervention: Telephone 'beep' intervention (short phone call not picked up)
Number of subjects: 471

Group type: COMPARATOR
Intervention: Control group (return to health facility for reporting)
Number of subjects: 471
Study: 23148885

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 34
Study: 21909371

Group type: EXPERIMENTAL
Intervention: Betel quid intoxication
Number of subjects: 12
Study: 18214504

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 101

Group type: COMPARATOR
Intervention: Lateral position
Number of subjects: 101
Study: 17009838

Group type: EXPERIMENTAL
Intervention: Fluid group (Bronchicum Elixir S, 6 x 5 ml daily)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Drops group (Bronchcium Tropfen, 5 x 1 ml daily)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Fluid group
Number of subjects: 189

Group type: COMPARATOR
Intervention: Drops group
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 189
Study: 14759070

Group type: EXPERIMENTAL
Intervention: T4 (100 microg daily)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: T3 (25 microg daily)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 11072156

Group type: EXPERIMENTAL
Intervention: C-RT (cisplatinum 40 mg/m(2)/weekly + radiation therapy)
Number of subjects: 8

Group type: COMPARATOR
Intervention: RT (radiation therapy alone)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: C-RT
Number of subjects: 8

Group type: COMPARATOR
Intervention: RT
Number of subjects: 8
Study: 8821843

Group type: EXPERIMENTAL
Intervention: Low‐flux biocompatible (BCM) membrane
Number of subjects: 159

Group type: COMPARATOR
Intervention: Low‐flux bioincompatible (BICM) membrane
Number of subjects: 159
Study: 1385010

Group type: EXPERIMENTAL
Intervention: Continuous high-dose aprotinin (7 x 10(6) KIU)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Single bolus of aprotinin (2 x 10(6) KIU)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Continuous high-dose aprotinin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Continuous high-dose aprotinin and Single bolus of aprotinin
Number of subjects: 50
Study: 30296887

Group type: EXPERIMENTAL
Intervention: Tapered Carotid Stents (TCS)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Straight Carotid Stents (SCS)
Number of subjects: 148
Study: 27480757

Group type: EXPERIMENTAL
Intervention: 1 × 10(10) colony-forming units of Lactobacillus rhamnosus GG, twice daily
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 24595780

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham-acupuncture (placebo)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No-acupuncture control
Number of subjects: 100
Study: 23431028

Group type: EXPERIMENTAL
Intervention: Ambulatory oxygen (AO) 2 L/min from a portable oxygen concentrator
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 20880433

Group type: EXPERIMENTAL
Intervention: 0.05% proparacaine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 18251212

Group type: EXPERIMENTAL
Intervention: Fixed-combination tablet of an ACE inhibitor (perindopril) with a diuretic (indapamide) (4 mg/l,250 mg)
Number of subjects: 11140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11140
Study: 16825335

Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 100
Study: 12809891

Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization of the prostate (TUVP)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 104
Study: 10678254

Group type: EXPERIMENTAL
Intervention: Physical Training (PT)
Number of subjects: 79
Study: 9010691

Group type: EXPERIMENTAL
Intervention: LIPO-PGE1 (50 micrograms bolus injection)
Number of subjects: 20

Group type: COMPARATOR
Intervention: PGE1-cyclodextrin (60 micrograms infusion over 2 hours)
Number of subjects: 20
Study: 1739236

Group type: EXPERIMENTAL
Intervention: Acetazolamide, 250 mg orally
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6377891

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg with meals three times daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 18
Study: 30128694

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging proton density fat fraction (PDFF) using 27 ROIs
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging proton density fat fraction (PDFF) using 9 ROIs
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Bland-Altman analysis for whole-liver PDFF measurement
Number of subjects: 45
Study: 29494790

Group type: EXPERIMENTAL
Intervention: Increase in flexible restraint
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Decrease in rigid restraint
Number of subjects: 61

Group type: COMPARATOR
Intervention: Disinhibition
Number of subjects: 61

Group type: COMPARATOR
Intervention: Hunger
Number of subjects: 61
Study: 26611571

Group type: EXPERIMENTAL
Intervention: Fluoxetine and saffron
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fluoxetine and placebo
Number of subjects: 40
Study: 25389751

Group type: EXPERIMENTAL
Intervention: Innovative approach to education embedding support for self-regulation in literacy, mathematics, and science learning activities.
Number of subjects: 759
Study: 22496115

Group type: EXPERIMENTAL
Intervention: Patient decision aid (PtDA) for vascular access
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study: 20013046

Group type: EXPERIMENTAL
Intervention: Parent-child reporting discrepancies on measures of child social phobia symptoms
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Treatment responder status
Number of subjects: 81
Study: 16472588

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg/20 mg
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Adalimumab 80 mg/40 mg
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Adalimumab 160 mg/80 mg
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study: 12858201

Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell transplantation (PBSCT)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: PBSCT with intermediate/advanced disease
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: PBSCT with lower proportion of advanced disease
Number of subjects: 7
Study: 11187565

Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: ANOVA
Number of subjects: 0
Study: 9604449

Group type: EXPERIMENTAL
Intervention: UVB plus 100 g of calcipotriol (50 micrograms/g) ointment per week
Number of subjects: 0

Group type: COMPARATOR
Intervention: UVB alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcipotriol ointment alone (100 g/week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy (UVB plus calcipotriol)
Number of subjects: 0
Study: 8409072

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg/day)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study: 2422467

Group type: EXPERIMENTAL
Intervention: tiapamil 1 mg/kg body weight
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: nisoldipine 6 micrograms/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: nifedipine 15 micrograms/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo (20 ml 0.9% NaCl)
Number of subjects: 20
Study: 31575503

Group type: COMPARATOR
Intervention: Gemcitabine 1000 mg/m2 and carboplatin (AUC 2 μg×h/mL) on days 1 and 8 (group 1)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Gemcitabine and carboplatin plus intravenous trilaciclib 240 mg/m2 on days 1 and 8 (group 2)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Gemcitabine and carboplatin on days 2 and 9 plus trilaciclib on days 1, 2, 8, and 9 (group 3)
Number of subjects: 102
Study: 28464321

Group type: EXPERIMENTAL
Intervention: DS-3801b 50 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 23556466

Group type: EXPERIMENTAL
Intervention: Early-invitation group (food supplements starting at ∼9 weeks gestation, 2.5 MJ d(‐1), 6 days a week)
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Usual-invitation group (food supplements starting at ∼20 weeks gestation)
Number of subjects: 1041
Study: 23114870

Group type: EXPERIMENTAL
Intervention: Custom-fit MRI-based pin guides
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intramedullary alignment jigs
Number of subjects: 80
Study: 21341920

Group type: EXPERIMENTAL
Intervention: Contingent group earning monetary vouchers for biochemical samples meeting smoking abstinence criteria
Number of subjects: 2

Group type: COMPARATOR
Intervention: Noncontingent group earning monetary vouchers independent of smoking status
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Contingent group with access to bupropion
Number of subjects: 2

Group type: COMPARATOR
Intervention: Noncontingent group with access to bupropion
Number of subjects: 2
Study: 20051716

Group type: EXPERIMENTAL
Intervention: Human rhinovirus infections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early rhinoviral wheezing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Viral infections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immune stimulation by rhinovirus infections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timing of allergen exposure
Number of subjects: 0
Study: 17309935

Group type: EXPERIMENTAL
Intervention: Calcium/vitamin D supplementation (500 mg calcium carbonate with 200 IU vitamin D twice daily)
Number of subjects: 36282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36282
Study: 15868107

Group type: EXPERIMENTAL
Intervention: Interactive Educational and Support Group programme (IESG)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (non-participants and those not invited to IESG)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: IESG
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 12184523

Group type: EXPERIMENTAL
Intervention: Synthetic motilin infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study: 9536937

Group type: EXPERIMENTAL
Intervention: Anti-H pylori treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omeprazole 40 mg/day for one month followed by 20 mg/day for six months
Number of subjects: 0
Study: 7634631

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily for 7 days postoperatively
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (no non-steroidal antiinflammatory drug)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study: 2647711

Group type: EXPERIMENTAL
Intervention: Ergoloid mesylates
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 869151

Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0‐125% or 0‐25% bupivacaine solutions
Number of subjects: 11
Study: 30521366

Group type: EXPERIMENTAL
Intervention: Standardized behaviors across a 5-day protocol in dim light
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Prior nocturnal sleep
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Prior rested wakefulness
Number of subjects: 26

Group type: COMPARATOR
Intervention: Maintained wakefulness
Number of subjects: 26
Study: 28342390

Group type: EXPERIMENTAL
Intervention: Lidocaine gel
Number of subjects: 80

Group type: COMPARATOR
Intervention: Aqueous gel
Number of subjects: 80
Study: 25941160

Group type: EXPERIMENTAL
Intervention: Linagliptin with insulin (mild renal impairment)
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Linagliptin with insulin (moderate renal impairment)
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Linagliptin with insulin (severe renal impairment)
Number of subjects: 811

Group type: COMPARATOR
Intervention: Linagliptin (mild renal impairment)
Number of subjects: 811

Group type: COMPARATOR
Intervention: Linagliptin (moderate renal impairment)
Number of subjects: 811

Group type: COMPARATOR
Intervention: Linagliptin (severe renal impairment)
Number of subjects: 811
Study: 23465039

Group type: EXPERIMENTAL
Intervention: EBDI tailored to motivational interviewing (MI) technique
Number of subjects: 991

Group type: COMPARATOR
Intervention: EBDI provided as usual
Number of subjects: 991
Study: 22470030

Group type: EXPERIMENTAL
Intervention: Antioxidant therapy (β‐carotene, vitamin C, vitamin E)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 19567761

Group type: EXPERIMENTAL
Intervention: Nurse-led intervention (N=47)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (N=53)
Number of subjects: 100
Study: 16691463

Group type: EXPERIMENTAL
Intervention: Group-based modeling approach for analyzing longitudinal data on substance abuse remission
Number of subjects: 0
Study: 15568960

Group type: EXPERIMENTAL
Intervention: Pediatric Vision Screener (PVS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (adults with binocularity scores >50%)
Number of subjects: 40
Study: 11341475

Group type: EXPERIMENTAL
Intervention: Tolterodine 2mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxybutynin 5mg 3 times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Once daily extended-release tolterodine capsules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 0
Study: 9022531

Group type: EXPERIMENTAL
Intervention: Fish oil concentrate (FOC) 5 g
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Purified eicosapentaenoic acid (EPA) 3 g
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (olive oil ethyl esters) 5 g
Number of subjects: 29
Study: 7889665

Group type: EXPERIMENTAL
Intervention: Ro 24-0238, 10% solution in diethylene glycol monoethyl ether
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3065929

Group type: EXPERIMENTAL
Intervention: Intramuscular ceftriaxone (CFT) 100 mg/kg once daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: Combined intramuscular ampicillin (160 mg/kg/day) and chloramphenicol (100 mg/kg/day) given every 6 h (AMC)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Intramuscular ceftriaxone (CFT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Combined intramuscular ampicillin and chloramphenicol (AMC)
Number of subjects: 70
Study: 4947831

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetylsalicylic acid
Number of subjects: 0
Study: 30502416

Group type: EXPERIMENTAL
Intervention: Clindamycin plus rifampicin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clindamycin alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60